Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iRhythm HoldingsIRTC -3.99%71 Debt-to-EBITDA is -41.36 as of Mar. 2026. GuruFocus rates IRTC with a GF Score™ of 71/100 and a GF Value™ of $164.31 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 469 Medical Devices & Instruments companies, iRhythm Holdings ranks worse than 99.15% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for iRhythm Holdings's Debt-to-EBITDA or its related term are showing as below:
IRTC'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -184.41 Med: -1.65 Max: 57.98
Current: 57.98
During the past 12 years, the highest Debt-to-EBITDA Ratio of iRhythm Holdings was 57.98. The lowest was -184.41. And the median was -1.65.
IRTC's Debt-to-EBITDA is ranked worse than 99.15% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs IRTC: 57.98
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
iRhythm Holdings Debt-to-EBITDA Related Terms
iRhythm Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for iRhythm Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRTC vs HAE, LIVN, ITGR: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, iRhythm Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iRhythm Holdings Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where iRhythm Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
iRhythm Holdings (IRTC) has a Debt-to-EBITDA of -41.36 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on iRhythm Holdings. According to the industry distribution chart, iRhythm Holdings ranks #465 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 99.1%.
Is iRhythm Holdings' Debt-to-EBITDA too high?
iRhythm Holdings' current Debt-to-EBITDA is -41.36. Based on the distribution chart, iRhythm Holdings ranks #465 out of 469 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, iRhythm Holdings has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does iRhythm Holdings' Debt-to-EBITDA compare to HAE and LIVN?
According to the Medical Devices & Instruments industry distribution chart, iRhythm Holdings ranks #465 out of 469 companies for Debt-to-EBITDA. This places iRhythm Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on iRhythm Holdings. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iRhythm Holdings's current Debt-to-EBITDA is -41.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRhythm Holdings stock overvalued right now?
Based on GuruFocus' analysis, iRhythm Holdings (IRTC) is currently considered Significantly Undervalued. The stock's GF Value™ is $164.31, compared to a current price of $110.88 — trading 32.5% below its estimated fair value. The current Debt-to-EBITDA is -41.36. iRhythm Holdings' overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For iRhythm Holdings (IRTC), the current Debt-to-EBITDA is -41.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iRhythm Holdings (IRTC) Overvalued in 2026?
Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued.
The current stock price of $110.88 is trading 32.5% below its estimated GF Value™ of $164.31.
GuruFocus considers iRhythm Holdings to be Significantly Undervalued.
Key valuation signals for IRTC:
Debt-to-EBITDA: -41.36
GF Value™: $164.31 vs. price of $110.88 (32.5% below fair value)
No single metric tells the full story. See the IRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
71GF Score
Get the complete analysis for IRTC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IRTC has been successfully added to your 
